Real-time US stock institutional ownership tracking and fund flow analysis to understand who owns and is buying the stock. We monitor 13F filings and institutional buying patterns because large investors often have superior information.
Catalyst Pharmaceuticals (CPRX) has recently traded near $31.15, reflecting a slight negative bias of 0.03% in a session marked by relatively normal volume compared to its historical average. The stock appears to be consolidating between established support at $29.59 and resistance at $32.71, a rang
Catalyst (CPRX) Unchanged at $$31.15 — Range-Bound Trading 2026-05-14 - Volume Breakout
CPRX - Stock Analysis
4465 Comments
1165 Likes
1
Debooah
Senior Contributor
2 hours ago
Can we start a group for this?
👍 103
Reply
2
Floriberto
Active Reader
5 hours ago
Volume spikes indicate increased trading interest, but long-term trends remain the main focus for many investors.
👍 226
Reply
3
Mber
Legendary User
1 day ago
This feels like something already passed.
👍 153
Reply
4
Vanya
Expert Member
1 day ago
Expert US stock fundamental screening criteria and quality metrics to identify companies with durable competitive advantages. Our fundamental analysis goes beyond simple ratios to understand the true drivers of long-term business value.
👍 283
Reply
5
Lotosha
Loyal User
2 days ago
Wish I had caught this earlier. 😞
👍 279
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.